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RESEARCH PROJECT 
 
Magnetic resonance imaging and hydrogen 1 MR spectroscopy  of the 
prostate gland are performed during the same examination with a 
conventional clinical MR unit.  
Prostate zonal anatomy and prostate cancer are best depicted on 
multiplanar T2-weighted MR images. MR imaging and 1H MR 
spectroscopy are not used as an initial diagnostic tool. Their use in 
tumor detection is reserved for patients with elevated prostate-specific 
antigen levels in whom previous biopsy results were negative. The use 
of MR imaging and 1H MR spectroscopy for the evaluation of tumor 
location, local extent (extracapsular extension and/or seminal vesicle 
invasion), volume, and aggressiveness is generating strong clinical 
interest.  
In staging and treatment planning, MR imaging has been shown to 
have an incremental value additive to the value of clinical 
nomograms. Furthermore, anatomic and metabolic mapping of the 
prostate gland with 1H MR spectroscopy offers the possibility of 
optimizing treatment planning (watchful waiting, surgery, or radiation 
therapy [intensity-modulated radiation therapy or brachytherapy]), 
thus further expanding the role of MR imaging in the achievement of 
patient-specific, individualized treatment. 
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INTRODUCTION 
 
Prostate cancer is the most frequent malignancy of the male 
genitourinary tract, with an incidence in Europe of approximately 30 
per 100.000 [48,49]. MRI of the prostate with a combined pelvic and 
endorectal coil has become an accepted method for staging prostate 
cancer. The advantages of this technique get results especially in local 
staging sensitivity, with a better judgement of surrounding structures 
[50,51]. Three-dimensional 1H-spectroscopy (3D MRS) of the 
prostate with evaluation of the metabolites choline, creatine, and 
citrate is a promising method for detecting prostate carcinomas which 
in particular show a higher choline and a reduced citrate level in 
comparison with healthy prostatic tissue [52,53].  
The first objective of our study was to assess sensitivity, specificity 
and accuracy of 3-D MRI and 3D MRS in patients with high prostate-
specific antigen (PSA) levels and biopsy proven prostate carcinoma, 
candidate to radical prostatectomy.  
The second purpose was to find a cut-off value of (Cho+Cr)/Cit ratio 
to discriminate between normal peripheral zone tissue and cancer.  
Besides we find a correlation between  (Cho+Cr)/Cit ratio and 
histologic Gleason score. 
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MATERIALS AND METHODS 
 
Patient Characteristics 
 
Our study included a total of 27 patients (median age, 65 years; age 
range, 48-77 years; median PSA, 10.37 ng/ml, PSA range, 4.2-39 
ng/ml) who underwent endorectal MRI and 3D-MRS followed by 
radical prostatectomy between January 2005 and February 2007. 
Informed consent was obtained from all patients according to an 
institutionally approved research protocol. Patients with a 
histologically proven prostate carcinoma and without any 
contraindications for MRI examination of the prostate were included 
in our study. Patients with previous surgery, radiation therapy or under 
ongoing hormonal therapy were not included. A minimum delay of 4-
6 weeks was required between biopsy and MRI and MRS to minimize 
biopsy artifacts. 
The average time elapsed between the combined MR and MRS 
examination and radical prostatectomy was 15 days. Following 
surgery, radical prostatectomy specimens were submitted for 
wholemount step-section pathologic evaluation. 
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MR Image Acquisition Protocol 
 
Imaging of the prostate was performed on a 1.5-T Siemens scanner 
(Magnetom Symphony Maestro; Siemens Medical Solutions, 
Erlangen, Germany) with a combined pelvic phased-array coil and 
endorectal coil (MRInnervu; Medrad, Indianola, USA). No contrast 
medium was used for imaging. The endorectal coil was inserted and 
inflated with approximately 60 ml air. No drugs was administered to 
reduce bowel motility. 
The sequence protocol consisted of transversal (tra), coronal (cor) and 
sagittal (sag) T2-weighted fast spin echo (FSE) sequences. T1-
weighted FSE sequence was used to detect the presence of post-biopsy 
haemorrhage and for assessing lymph node status of the pelvis.  
 
Sequence data 
 
– T2w FSE tra: turbo factor 23, TR 4300 ms, TE 117 ms, slice 
thickness 3.0 mm, FoV 160 mm, Gap 0.8 mm, matrix 230x256, NEX 
2, scan time  4’32’’ 
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– T2w FSE sag: turbo factor 25, TR 3500 ms, TE 107 ms, slice 
thickness 3.0 mm, FoV 200 mm, Gap 0.8 mm, matrix 224x320, NEX 
2, scan time  3’55’’ 
– T2w FSE cor: turbo factor 25, TR 3500 ms, TE 107 ms, slice 
thickness 3.0 mm, FoV 180 mm, Gap 0.8 mm, matrix 256x256, NEX 
2, scan time  4’25’’ 
– T1w FSE tra: turbo factor 3, TR 500-600 ms, TE 15 ms, slice 
thickness 3.0 mm, FoV 160 mm, Gap 0.8 mm, matrix 196x256, NEX 
2, scan time  4’19’’ 
 
Three-dimensional 1H-spectroscopy (3D MRS) 
 
MRS data were acquired by a three-dimensional chemical shift 
imaging (3D CSI) double spin-echo point-resolved spatially localized 
spectroscopic (PRESS) sequence [54] on a Magnetom Symphony 
Maestro 1.5-T scanner (Siemens Medical Solutions). The body coil 
was used for homogenous excitation, and an endorectal coil for signal 
reception, granting maximum signal-to-noise ratio (SNR). TE = 120 
ms allowed in-phase detection of the citrate signal. We resorted to k-
space weighted acquisition to make optimal use of the scan time: For 
TR = 1.300 ms and four averages, the scan time was 11 min 12 s. 
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Along the spatial dimensions a Hamming filter was applied. The voxel 
size was 6.7×6.7×6.7 mm3. The field map-based automatic shimming 
procedure of the system was applied. The VoI was positioned closely 
around the prostate, and a reference frequency corresponding to 2.9 
ppm (i.e., the centre of the citrate and choline resonances of interest) 
was used. Additionally, simultaneous spectral suppression of the water 
and the lipid signals was performed and up to eight spatially selective 
saturation bands were interactively positioned. We obtained integral 
values by fitting Gaussian lineshape functions to the resulting 
absorption spectra. For further analysis, integral ratios were used 
(Cho+Cr)/Cit. The spectral grid was superimposed on the reference 
images in transversal, coronal and sagittal orientations. The spectra 
were automatically post-processed and reconstructed with 
commercially available software. 
In patients with histologically proven prostate carcinoma we indicated 
the voxels covering tumorous lesions as “malignant voxels”; voxels 
covering non suspicious prostate tissue were defined as “normal 
voxels”. 
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Histopathologic analysis 
 
Prostatectomy specimen whole-mount preparation consisted of its 
fixation in 10% formalin for 36 hours. The distal 5-mm portion of the 
apex was amputated and coned. The remainder of the gland was 
serially sliced from the apex to the base at 3–4 mm intervals, and 
slices were submitted for paraffin embedding as whole mounts. The 
seminal vesicles were amputated and submitted separately. After 
paraffin embedding, micro-slices were placed on glass slides and 
stained with haematoxylin and eosin. At pathologic analysis, a 
Gleason score was assigned to the whole cancer in the specimen 
according to the current clinical protocol at our institution. Besides, 
cancer foci were outlined  by the pathologist with ink on whole-
mount, apical, and seminal vesicle slices so to result grossly visible, 
and then photographed. These histological findings constituted our 
tumour maps.  
 
Data analysis 
 
All T2wi, T1wi and spectroscopic data sets were prospectively 
evaluated by two radiologists with different levels of experience in 
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evaluating prostate MR images and without prior knowledge of the 
PSA level or biopsy results. 
Subsequently, after radical prostatectomy followed by histopathologic 
analysis, MR images and spectra previously obtained were compared 
with the results of pathologist by the same two radiologists in 
consensus. This correlation was performed just evaluating the whole 
right and the whole left lobe of the prostate. Lesions resulted 
malignant at histopathology and located within the apex or middle 
gland or in prostatic base were considered as involving the entire lobe.  
The same criteria was applied during the MR and MRS interpretation. 
This was to avoid erroneous samples obtained during trans-rectal US 
biopsy and leading to incorrect results. 
At least, we merged the T2w MR images with the whole-mount 
sections. We used as landmarks the morphology of the gland  and its 
normal anatomy, with particular regards to the apex, the base and the 
urethra. Thank to this accurately fusion we could consider as surely 
malignant those voxels completely enclosed within the tumorous zone 
outlined in ink from pathologist and as negative ones all the others.  
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Statistical analysis 
 
Sensitivity, specificity and accuracy of biopsy, MRI, MRS and 
MRI+MRS readings were correlated with pathology results (gold 
standard); our data were calculated using a stastical software.  
We entered the data of different variables (biopsy, MRI, MRS, 
MRI+MRS) in columns of the spreadsheet of the software and we 
correlated them with the gold standard variable (histopathology). We 
calculated sensitivity and specificity,  accuracy, PPV and NPV for all 
possible threshold values. 
To evaluate the concordance between the different diagnostic methods 
and the histopathologic results, we compared true positive data of 
biopsy, MRI alone, MRS alone and combined MRI+MRS with the 
results of histopathology, using Cohen’s test and we obtained a K 
value for each comparison. 
Retrospectively and related to pathologic results, we used ROC curves 
to calculate a cut-off value of (Cho+Cr)/Cit ratio that allowed us to 
discriminate between cancer and normal prostatic tissue in the 
peripheral zone. 
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RESULTS 
 
26 of 27 patients who underwent MRI and MRS followed by radical 
prostatectomy,  were included in the final analysis of spectroscopy 
data. Step section histopathology demonstrated stage pT2 disease in 
18 patients, pT3 in 4 patients (unilateral extracapsular extension n=2, 
bilateral n=0, seminal vesicle extension n=0), pT4 in 4 patients. 
In these 26 patients, a total of 43 locations of cancer were identified 
with step-section pathologic evaluation. Biopsy correctly detected 37 
locations with 6 false-negative and 3 false-positive findings 
(sensitivity of 86%, specificity of 67%, accuracy of 83%, negative 
predictive value of 50%, and positive predictive value of 92%); MRI 
correctly detected 36 locations with 7 false-negative and 1 false-
positive findings (sensitivity of 84%, specificity of 89%, accuracy of 
85%, negative predictive value of 53%, and positive predictive value 
of 97%); MRS correctly detected 36 locations with 7 false-negative 
and 2 false-positive findings (sensitivity of 84%, specificity of 78%, 
accuracy of 83%, negative predictive value of 50%, and positive 
predictive value of 95%); MRI+MRS correctly detected 39 locations 
with 4 false-negative and 2 false-positive findings (sensitivity of 91%, 
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specificity of 78%, accuracy of 88%, negative predictive value of 
64%, and positive predictive value of 95%).  
Sensitivity, specificity, accuracy and positive and negative predictive 
values of biopsy, MRI, MRS and MRI+MRS for lobar localization of 
prostate cancer are listed in table 1 and histogram in figure 14 shows 
the gain in sensitivity, specificity, accuracy, PPV and NPV of 
MRI+MRS than biopsy . 
    
 
 
 
 
 
 
 
 
Table 1. Sensitivity, specificity, accuracy  and positive and negative predictive 
values of biopsy, MRI, MRS and MRI+MRS for lobar localization of prostate 
cancer. 
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Fig.14.The histogram shows true positive (TP), true negative (TN), false positive 
(FP) and false negative (FN) value of the different methods compared with 
histology. Combined MRI and MRS shows a gain in TP and reduction on FP and 
FN compared with biopsy. 
 
  
 
% Sensitivity  Specificity %Accuracy  %P P V  %N P V 
Biopsy 86 67 83 92 50 
MRI 84 89 85 97 53 
MRS 84 78 83 95 50 
MRI+MRS 91 78 88 95 64 
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Using Cohen’s test we compared the true positive values of the 
different diagnostic thecniques (biopsy, MRI and MRS alone and 
MRI+MRS) with the histopathologic results, to evaluate the degree of 
agreement between the differents diagnostic methods and the gold 
standard (histology). Cohen’s test showed that biopsy had a lower 
degree of agreement with histology than MRI+MRS combined (0.559, 
moderate agreement versus 0.735, good agreement) [55] (table 2). 
 
 K-value 
Biopsy 0.559 
MRI 0.581 
MRS 0.563 
MRI+MRS 0.735 
                   
                                Table 2. Cohen’s test 
 
  
 Retrospectively basing on whole-mount sections and using a 
dedicated software we merged hystopathologic sections with the 
corresponding T2w images in order to obtain “neoplastic spectra” 
(n=37) from the malignant voxel exactly enclosed within the 
neoplastic area outlinked in ink from pathologist, and “control 
spectra” (n=66) from the voxels out of the signed neoplastic areas (fig 
15).                                                                                                                     
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. We obtained also related (Cho+Cr)/Cit ratios; the mean peak area 
ratio of (Cho+Cr)/Cit in tumorous lesions was 2,74 (± 4,6) and in 
control voxels 0.25 (± 0.16). The difference regarding the 
(Cho+Cr)/Cit ratio was highly significant between tumour and control 
voxels  (p<0.001).  
                      
                                                
Fig.15. Fusion imaging of histology, MRI and MRS and related neoplastic 
spectrum. 
 
 
We classified the obtained spectra as normal if (Cho+Cr)/Cit ratio was 
<2 SD, uncertain if ratio was <2-3SD> and pathologic if ratio was >3 
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SD from the normal. On this basis we find a cut-off value (0.47) that 
may be used to discriminate between normal tissue (<2 SD or <2-3 
SD>) and cancer (>3 SD) in peripheral zone (table 3). 
The ROC curve confirmed our cut-off as a very good one (sensitivity 
100%, specificity 89.4 (figure 16). 
 
 
 
 
      (Cho+Cr)/Cit 
Normal < 0.47 
Cancer > 0.47 
 
Table 3: The cut-off value for (Cho+Cr)/Cit ratio. 
 
 
 
 
                          
 
Figure 16. Sensitivity and specificity of ROC curves 
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Furthermore we classified patients of our study basing on Gleason 
score resulting from histologic analysis. We obtained five degree of 
Gleason score (3+3, 3+4, 4+3, 3+5 and 4+5). For each group we 
plotted the different values of  Cho+Cr)/Cit ratio and we demostrated 
(fig.17) a significative correlation between (Cho+Cr)/Cit ratio and 
Gleason score (r=0.5816, p<0.0001). 
 
 
        Figure 17. Correlation between (Cho+Cr)/Cit ratio and Gleason score. 
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DISCUSSION 
 
MR imaging keep on evolving in the diagnostic evaluation of prostate 
cancer. It has found a role as a local staging modality for 
differentiation between patients with organ-confined cancer and those 
with extracapsular tumor extension [56]. New treatment strategies (eg. 
imaging-guided brachytherapy [57], laser therapy [58], and 
cryotherapy [59]) and the concept of watchful waiting [60] require an 
extension of diagnostic imaging beyond staging to providing more 
precise information about tumor presence and location. Accurate 
tumor localization will allow greater intensity of treatment to areas of 
the prostate gland where cancer is present, which will ideally increase 
the effectiveness of treatment while reducing treatment-related 
morbidity. In addition, information about tumor growth with accurate 
tumor localization and sizing may also assist selection and 
maintenance of a watchful waiting strategy that may obviate repeated 
biopsies. Knowledge of tumor location may also be of use in patients 
with elevated prostate-specific antigen level but repeatedly negative 
findings at prostatic biopsy. In that clinical setting, knowledge of 
tumor location may help guide future biopsies.  
Current diagnostic strategies have limitations in tumor detection and 
localization. Transrectal US fails to depict as many as 8%–30% of 
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lesions palpable at digital rectal examination. Transrectal US also has 
a high false-positive rate in cancer evaluation because only 20% of 
hypoechoic lesions (US finding most indicative of cancer) are 
malignant [61]. MR imaging with a combined endorectal and phased-
array coil has demonstrated a high sensitivity (91%) but low 
specificity (27%) in tumor lateralization [5]. Initial reports about 3D 
MR spectroscopic imaging show that the ability of this technique to 
distinguish between cancer, benign prostatic hypertrophy, and normal 
prostatic tissue suggests that the addition of MRS to clinical MRI may 
increase the specificity of MR imaging in tumor detection and 
localization [62].  
In our study, we evaluated this hypothesis by correlating results with 
MRI, MRS alone, or both to those with step-section histopathologic 
examination in patients who underwent prostatectomy.  
Data points on the histogram indicated a significantly better 
performance with combined MRI and MRS than with MRI alone. 
MRI+MRS demonstrated a better sensitivity and accuracy in tumor 
localization respect to MRI alone. The accuracy we obtained using 
combined MRI and MRS for tumor lateralization (right or left 
prostatic lobe) was 88%, as indicated on literature [47]. A negative 
result with combined MRI and MRS excluded the presence of cancer 
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with high probability (negative predictive value, 64% VS 53% of MRI 
alone) (Fig.15). 
 
 
 
 
 
 
 
 
 
 a                                                          b              
 
 
 
 
 
 
 
 
 
 c                                                         d 
 
 
 
 
 
 
 
 e  
Fig.15 Axial T2- weighted images from an FSE sequence of a 61-year-old patient 
with a PSA level of 8.7 ng/ml and a histologically proven prostate carcinoma of 
the right side (e) with demonstration of a tumour voxel (a,b) and a control benigne 
voxel from the opposite side (c,d). 
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Our study showed also that we can use the cut-off value of 
(Cho+Cr)/Cit ratio of 0.47 to discriminate between cancer and normal 
prostatic tissue in the peripheral zone (sensitivity 89.2%; specificity 
91%, p=0.0001). 
Preliminary findings suggest that small, low-grade tumors may be 
undetected with MRS because the severity of metabolite alteration 
correlates with tumor aggressiveness. High-grade cancers (Gleason 
scores 7 and 8) revealed highly elevated choline resonances, whereas 
lower grade tumors (Gleason scores 4 and 5) showed slightly elevated 
choline levels only [63]. 
However our study had some limitations, including a small number of 
patients. Two radiologists compared the tumor locations with the 
histopathologic data after having read MR an MRS images, and this 
may have introduced information bias. 
Furthermore our experience with MRS increased during the study and 
thereby resulted in improved quality of the spectra and reduced 
examination time; however these factors were not evaluated in detail. 
MRI was performed after prostate biopsy, with at least 4 weeks 
between the two procedures. This factor may have introduced spectral 
degradation [64]. 
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Moreover it is important to stress the fact that traditionally sextant 
biopsy has been regarded as the standard of reference for nonsurgical 
cancer localization [65]. In our experience we have noticed that the 
reality is not always this one. In fact sextant biopsy has some 
important limitations which cannot be forgotten, for example its 
completely dependency by the operator but most important its limited 
sensitivity due to sampling error expecially in the prostate apex. In 
particular, this last result is probably associated with under sampling 
the apex during transrectal ultrasound guided biopsy since the prostate 
apex is smaller and less easily visualized, and at biopsy the sample is 
obtained from the tissue superior to the needle tip [66,67]. 
On the other hand, these increasingly recognized limitations of sextant 
biopsy has provoked interest in endorectal MRI and MRS as 
alternative methods of tumor evaluation, expecially when MRI and 
MRS are performed in a combined way [68]. 
Logically we are not suggesting that MRI plus MRS should replace 
sextant biopsies for tumour diagnosis, but we have noticed that all the 
methodological problems intrinsic to the sampling technique is putting 
sextant biopsies in an unfair light in regard to MRI with MRS.  
We believe the clinical implications of improved prostate cancer 
localization with MRS apply (a) for patients with increasing prostate-
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specific antigen levels and negative US-guided biopsy (for 
souspicious lesions) results; (b) for evaluation of tumor location and 
of the distance to the neurovascular bundle and the prostate capsule to 
determine if nerve-sparing surgery is possible; and (c) for planning of 
intensity-modulated radiation therapy [69] , which requires exact 
localization of the prostate cancer to administer an extra boost of 
radiation in addition to the normal dose. 
In conclusion, findings in this study demonstrate the potential 
usefulness of combined morphologic and metabolic information about 
prostate cancer in clinical practice and provide an analysis of this new 
method. Our findings showed that the addition of MRS to MRI 
provides better detection and localization of prostate cancer, with 
sensitivity, accuracy and NPV higher than those with MR imaging 
alone. This suggest that if this technique is included in the MR 
imaging protocol, the localization of prostate cancer in patients will 
improve.  
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